- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05945979
Evaluation of the Efficacy of a New Supplement for Hair and Nails - in Vitro, Clinical, Subjective and Instrumental Study
Avaliação da eficácia de um Novo Suplemento Alimentar Para Cabelos e Unhas- Estudo in Vitro, clínico, Subjetivo e Instrumental
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A unicentric, exploratory, prospective clinical an in vitro study to evaluate efficacy and safety of a Supplement in improving the quality and general aspects of hair and nails in female participants through clinical, in vitro, subjective and instrumental evaluations.
It will be necessary 40 female participants aged between 25 and 55 years old with a clinical and in vitro diagnosis of telogen effluvium presenting at least one of the following characteristics: hair loss problems caused by stress, poor diet and excess of tinctures and chemicals procedures applied to hair, and menopausal women.
The participants will remain in the study for 93 days using the product. Visits will be scheduled in D-3, D0, D45, D48, D90, D93.
Instrumental evaluations: Evaluated on each visit:
- To analyze the biological cycle of hair growth using Trichogram test - D-3, D45, D90;
- Evaluation of hair growth kinetics using phototrichogram - D-3,D0, D45, D48, D90, D93;
- Evaluation of the mechanical strength of the hair structure using EMIC DL 500- D-3, D90
- Evaluation of the dermal density of the scalp using the high-frequency ultrasound- D-3, D45, D90
- Participants will respond to a subjective assessment using a questionnaire to capture a subjective efficacy- D45, D90
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
São Paulo
-
Valinhos, São Paulo, Brazil, 13270-180
- Kosmoscience Ciência e Tecnologia Cosmética Ltda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Phototype (Fitzpatrick): I to VI.
- Have intact skin in the test region: scalp.
- Present a clinical diagnosis of telogen effluvium.
- Agree to adhere to the study procedures and requirements: study time, returns (D-3, D0, D45, D48,D90 and D93) to the laboratory to carry out the study procedures, administration of the product research, fill the use diary, fill the perceived efficacy questionnaire, carrying out the collection of hair samples (hair cut, close to the scalp - beginning of the study and after 90 days), not change hair habits during the study period.
- Agree not to carry out chemical hair treatments (hair coloring, straightening, among others) and/or treatment to control/reduce hair loss and/or dandruff, among others, until the end of the study (90 days).
- Agree with the procedure for collecting hair samples: trichogram and hair cut, close to the leather hairy.
- Agree to administer 01 capsule/day of the investigational product. Present a minimum length of hair (3 cm) to carry out the procedure for collecting samples of hair
- Present hair and brittleness for at least 3 months before the start of the study.
- Signature of the Free and Informed Consent Term (TCLE).
Exclusion Criteria:
- Pregnancy
- During the course of the study, the subject develops symptoms of COVID-19, such as: fever (temperature above 37.5°C), cough; dyspnoea (difficulty breathing characterized by rapid, short breaths, usually associated with heart or lung disease); myalgia (muscle pain); upper respiratory symptoms; fatigue and more rarely, gastrointestinal symptoms.
- Appearance of disease that requires the use of medications prohibited in this protocol: use of corticoids and anti-inflammatories for a period longer than 15 days and/or in high doses (above 1mg/kg).
- Use of immunosuppressants during the study period.
- Use of Vitamin A or its derivatives and other vitamins and minerals.
- Beginning or changing hormone treatments after signing the TCLE.
- Swallowing difficulty: dysphagia.
- Presence of dermatoses or active skin lesions (local and/or disseminated) in the study region.
- Hypersensitivity reactions (allergic reactions, irritation or feelings of discomfort) caused by actives or excipients from the investigational product.
- Vaccine use during the study period.
- Diagnosis of diabetes or nephropathies during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A power supplement with biotin
40 participants using the product for 90 days.
Aims to evaluate the clinical, subjective and instrumental usage
|
A power dietary supplement containing aminoacids and vitamins
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate efficacy of a power supplement in reducing hair loss throgh thichogram analysis
Time Frame: Day 93
|
Evaluate the effectiveness of the product investigational in providing reduction of hair loss through thrichogram analysis.
If the ratio between anagen/telogen hairs strands is > 4, it indicates improvement in reducing hair loss after daily and continuous use for a period of up to 90 days.
|
Day 93
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of the biological cycle of hair growth- Trichogram
Time Frame: Three days before the beginning of product intake, Day 45 and Day 90
|
Evaluate the phase of the biological cycle of hair growth (anagen, telogen or catagen) and determine the ratio between anagen/telogen hair strands.
If the ratio between anagen/telogen hairs strands is ≤ 4, it indicates positive symptoms for androgenetic alopecia or telogen effluvium and the partipant will be included in the study.The trichogram was performed three days before the beginning of product intake, and after 45 days and 90 days of continuous use.
|
Three days before the beginning of product intake, Day 45 and Day 90
|
Evaluation of hair growth kinetics- Phototrichogram
Time Frame: Three days before the beginning of product intake, Day 0, Day 45, Day 48, Day 90 and Day 93
|
Evaluate the growth kinetics of hair strands after shaving a standardized area of 1 cm² of the scalp and taking images on the same day and three days after.
In total, three scrapings were performed on three days before intervention, day 45 and day 90, totaling six image collections.
A microscope (i-Scope USB, Moritex, JP) with a 30x lens and polarized light was used to obtain the images.
In each collection, three microimages of the evaluated area on the head of each participant were recorded.
|
Three days before the beginning of product intake, Day 0, Day 45, Day 48, Day 90 and Day 93
|
Monitoring of hair growth by photographic documentation
Time Frame: Day 0, Day 45 and Day 90
|
Evaluation of the dermal thickness of hair strands through specific software.
Patients will be submitted to the Ultrascan UC 22 MHz equipment (Courage + Khazaka electronic GmbH), on day 0 and after 45 days and 90 days of continuous use of the investigational product.
|
Day 0, Day 45 and Day 90
|
Evaluation of the mechanical strength of the hair structure using EMIC DL 500
Time Frame: Three days before the beginning of product intake and Day 90
|
Evaluation of the mechanical resistance of the hair.
50 hairs strands were collected from each participant and cut with the aid of scissors to avoid possible damage to the hair shaft resulting from traction for pulling out.
The test was performed three days before the beginning of product intake and after 90 days of continuous use.
|
Three days before the beginning of product intake and Day 90
|
Subjective efficacy of the participants by questionnaire
Time Frame: Day 45 and Day 90
|
Evaluate the perceived efficacy of the product from the participant's point of view through a subjective questionnaire after 45 days e 90 days of continuous use of the product.
The questionnaire uses a 7-point scale, where 1 meaning poor and 7 means excellent.
|
Day 45 and Day 90
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FQM166-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nails, Ingrown
-
Universidad de ExtremaduraUniversity of ValenciaCompleted
-
Rosalind Franklin University of Medicine and ScienceUnknownIngrown NailUnited States
-
Taipei Medical University WanFang HospitalUnknown
-
Universidad Complutense de MadridUnknownIngrown ToenailSpain
-
Michael LivingstonThe Physicians' Services Incorporated FoundationUnknown
-
Zagazig UniversityCompletedIngrown Toenail
-
Universidad Complutense de MadridCompletedSkin Diseases | Nail Diseases | Nails, IngrownSpain
-
Goztepe Training and Research HospitalCompleted
-
TCI Co., Ltd.RecruitingSkin Condition | Nails, Ingrown | Hair FragilityTaiwan
-
University of MalagaCompletedNails, Ingrown | Hyaluronic AcidSpain
Clinical Trials on A power supplement with biotin
-
Farmoquimica S.A.Medcin Instituto da Pele LtdaCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingMetabolic Syndrome | Severe ObesityFrance
-
McMaster UniversityRecruitingHealthy | Muscle Disuse AtrophyCanada
-
PEMF Systems, Inc.Henry Ford Health SystemTerminatedVenous Stasis UlcersUnited States
-
Water Pik, Inc.Completed
-
NovoBliss Research Pvt LtdOrgenetics, Inc.RecruitingDry Skin | Dry Hair | Hair Falling | Thin Hair | Brittle HairIndia
-
Hospital de MataróNutricia ResearchRecruitingStroke | Oropharyngeal Dysphagia | Swallowing DisorderSpain
-
Essilor InternationalElite School of Optometry and Sankara NethralayaCompleted
-
University Hospital Schleswig-HolsteinProcter and GambleCompletedGingival Recession
-
Universidad del Valle, ColombiaUniversidad de AntioquiaUnknownMuscle Weakness | Muscle LossColombia